Ocular Research Center

Our ocular research center is a one-of-a-kind model. It is the first and only combined eye bank and ocular research center in the world. Our research center empowers researchers to conduct real-time studies of healthy and diseased ocular tissue. This breakthrough model answers a critical need by providing normal and diseased human eye tissue to advance our understanding of events that lead to blindness. We collaborate with industry and leading institutions to develop a new pre-clinical research model offering unparalleled quality and volumes of human ocular tissue and unique research facilities for pharmaceutical or medical device studies.


Research Newsletter Archive

Research Tissue


  • Human eye tissue for research, surgical training, clinical advancement and collaboration
  • A database of each tissue and its clinical familial medical information – the only comprehensive database of its kind
  • Diseased as well as healthy human eye tissue available for research
  • Research opportunities involving whole globes, corneas, lenses, sclera, retinas/RPE, trabecular meshwork, optic nerves, endothelial cells and other areas


On Site Colaboration


  • Academic, pharmaceutical and medical device researchers can conduct on-site evaluations and initial tissue preservation, yielding better experimental results.
  • On-site capabilities using human ocular tissue will greatly reduce the post-mortem time interval, which is extremely critical in research studies.
  • The new facility provides advanced equipment and research lab space with state-of-the-art air filtration for an optimal lab environment.
  • LEITR will drive the development of new diagnostic tests and pharmacologic treatments for delaying, arresting and preventing progression of ocular diseases.
  • Hotel-style sleep suites for 24/7 on-site laboratory access.


Ocular Research Advancements

Attention: open in a new window.

LEITR at ARVO 2012

SIG Session 246: “Importance and Multiple Uses of Human Donor Eye Tissues in Ophthalmic Research”

Attention: open in a new window.

Surface Area Coverage of Suprachoroidal Injections Using A Hollow Microneedle in Fresh Human Globes

Samirkumar R. Patel1, Lousie Bergman2, Lennart C. Berglin2, Damian E. Berezovsky3, Xi Wang3, Jason K. Woody4, Mark R. Prausnitz1, Henry F. Edelhauser3

Attention: open in a new window.


Gary SL Peh1, Kah Peng Th1, Fei Yi Wu1, Donald T Tan1,2, Jodhbir S Mehta1

Attention: open in a new window.

Microkeratome Versus Femtosecond Laser Predissection of Corneal Grafts for Anterior and Posterior Lamellar Keratoplasty

Olan Suwan-apichon, MD,*† Johann M. G. Reyes, MD,* Neil B. Griffin, MD,‡ Jerry Barker, BS,‡ Patrick Gore, RN,§ and Roy S. Chuck, MD, PhD

Attention: open in a new window.

Eye Bank Preparation, Injector Cartridge Pre-Loading, Shipping and Cold Storage of DSAEK Grafts: A Laboratory Study of Endothelial Survival

Hyung Cho1, Sunju Park1, Alan Fong1, David C. Gritz1, Cheng Zhang1, Alexandra Herzlich1, Gibran Mian1, Patrick Gore2, Ashley Morganti2, Roy Chuck1.

Research Partners

With our model of ocular research, we seek to become a magnet to attract the leading researchers and scientific talent and contribute to the discovery of new breakthrough cures for blinding eye diseases. Click on the links to our partners or contact us to become a partner.

alcon glaukos
allegrgan harvard
Bausch novartis
emory uf

What do Opinion Leaders say about The Ocular Research Center?

The benefit of conducting studies at the Lions Eye Institute for Trasplant and Research is our ability to obtain human eyes within two to four hours of post-mortem time.

Our current studies are evaluating the distribution of various drugs and antibodies used in the treatment of AMD following a single microneedle injection into the suprachoridal space. These studies will show the similarities and/or differences in drug delivery compared to rabbit and pig eyes.

—Dr. Henry Edelhauser, Professor at Emory University Eye Center

Through LEITR, we will now have an unprecedented ability to access ocular tissue, which will undoubtedly facilitate new discoveries and future therapies.

—Mark S. Humayun, MD, PhD, Cornelius Pings Professor of Biomedical Sciences, Professor of Ophthalmology, Biomedical Engineering, Cell and Neurobiology Doheny Eye Institute, University of South California

Contact us at research@lionseyeinstitute.org to discuss your research needs.